CambriaTech Genomics (CTG):

Launched in 2001, CambriaTech Genomics (CTG) is CambriaTechs flagship programme (For more information, please visit: http://www.cambriatech.com/<*dv_4*>) in the biotechnology sector an ambitious company comprising a number of technology development opportunities, ranging from small molecule discovery to mitochondrial therapeutics.  CTG brings together leading scientists from some of the top universities in the US - each one a pioneer in his field of research and each one an active participant, shareholder and technical lead in his respective programme.  Research and development activities are being conducted in conjunction with the universities that have granted CTG portfolio companies exclusive field of use licenses for patented technologies.  Participating universities within the CTG initiative include Yale, Rensselaer Polytechnic Institute and Emory.

Yale University

<*dv_0*>Yale University is one of the most prestigious Universities in the world and has a strong history of scientific discovery and innovation.  <*dv_3*>For more information, please go to: www.yale.edu

Chiesi Farmaceutici

The Chiesi family founded the Chiesi Group in 1935.  Today it has 2300 employees and is represented by 12 subsidiaries located in many European countries, including United Kingdom, France, Spain, Greece, Italy and Austria.  The two principal locations of Research & Development are in Paris and Parma.  The major therapeutic sectors where Chiesi Farmaceutici operates are: respiratory diseases, cardiovascular and metabolic disorders, inflammation and musculo-skeletal and central nervous system.  For more information, please go to: http://www.chiesigroup.com/

Sigma-tau

Sigma-tau, founded in 1957, became a leading Italian pharmaceutical company within a few years, and is now an international organization looking at worldwide markets with great interest.  Sigma-tau recognizes the importance of R&D as a key factor for its growth and has consistently invested a significant share of its turnover in this field, reaching 18% of total turnover in recent years.  For more information, please go to: http://www.sigmatau.com/

Rottapharm Group

The Rottapharm Group was created in 1961 by Professor Luigi Rovati in Italy with the goal to pursue innovative research and development programs in the pharmaceutical field.  The first laboratory was built in Monza and 18 years later two laboratories were established in Germany and Portugal.  Today, Rottapharm is present in Italy, Germany, Portugal, Spain, France and Ireland, as well as in America, Asia and Oceania.  Rottapharm is focused in the therapeutic areas of rheumatology, cardiovascular and gastroenterology among others.  Many marketed products include antibacterial drugs such as Neotetramase, Monocid, and Ceprimax.  Rottapharm employs 1100 people worldwide.  <*dv_1*> For more information, please go to: http://www.rotta.com/